IGF System and Breast Cancer

  • Marc A. Becker
  • Douglas YeeEmail author
Part of the Cancer Drug Discovery and Development book series (CDD&D)


The insulin-like growth factor (IGF) pathway stimulates tumorigenesis and growth in breast cancer cells and can play a pivotal role in malignant progression. As a result, clinical efforts to target IGF action, namely via receptor-based strategies, are currently underway. While IGF-targeted therapies have shown activity in early clinical trials, benefits are seen in only a minority of patients suggesting that IGF pathway markers beyond the type I IGF receptor (IGF-1R) alone may improve patient stratification. This overview evaluates multiple facets of IGF pathway contribution in breast tumors and examines both current and future obstacles facing the clinical advancement of IGF-targeted therapeutics.


Breast Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Ahn, B. Y., A. N. Elwi, B. Lee, D. L. Trinh, A. C. Klimowicz, A. Yau, J. A. Chan, A. Magliocco, and S. W. Kim. 2010. Genetic screen identifies insulin-like growth factor binding protein 5 as a modulator of tamoxifen resistance in breast cancer. Cancer Res 70:3013–9.PubMedCrossRefGoogle Scholar
  2. Alexia, C., G. Fallot, M. Lasfer, G. Schweizer-Groyer, and A. Groyer. 2004. An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis. Biochem Pharmacol 68:1003–15.PubMedCrossRefGoogle Scholar
  3. Amemiya, Y., W. Yang, T. Benatar, S. Nofech-Mozes, A. Yee, H. Kahn, C. Holloway, and A. Seth. 2010. Insulin like growth factor binding protein-7 reduces growth of human breast cancer cells and xenografted tumors. Breast Cancer Res Treat.Google Scholar
  4. Araki, E., M. A. Lipes, M. E. Patti, J. C. Bruning, B. Haag, 3rd, R. S. Johnson, and C. R. Kahn. 1994. Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene. Nature 372:186–90.PubMedCrossRefGoogle Scholar
  5. Arteaga, C. L., L. J. Kitten, E. B. Coronado, S. Jacobs, F. C. Kull, Jr., D. C. Allred, and C. K. Osborne. 1989. Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest 84:1418–23.PubMedCrossRefGoogle Scholar
  6. Bae, M. H., M. J. Lee, S. K. Bae, O. H. Lee, Y. M. Lee, B. C. Park, and K. W. Kim. 1998. Insulin-like growth factor II (IGF-II) secreted from HepG2 human hepatocellular carcinoma cells shows angiogenic activity. Cancer Lett 128:41–6.PubMedCrossRefGoogle Scholar
  7. Baglietto, L., D. R. English, J. L. Hopper, H. A. Morris, W. D. Tilley, and G. G. Giles. 2007. Circulating insulin-like growth factor-I and binding protein-3 and the risk of breast cancer. Cancer Epidemiol Biomarkers Prev 16:763–8.PubMedCrossRefGoogle Scholar
  8. Beatson, G. T. 1896. On the treatment of inoperable cases of carcinoma of the mamma. Suggestions for a new method of treatment with illustrative cases. Lancet 2:104–107.Google Scholar
  9. Bermont, L., S. Fauconnet, F. Lamielle, and G. L. Adessi. 2000. Cell-associated insulin-like growth factor-binding proteins inhibit insulin-like growth factor-I-induced endometrial cancer cell proliferation. Cell Mol Biol (Noisy-le-grand) 46:1173–82.Google Scholar
  10. Bingham, S., and E. Riboli. 2004. Diet and cancer--the European Prospective Investigation into Cancer and Nutrition. Nat Rev Cancer 4:206–15.PubMedCrossRefGoogle Scholar
  11. Bohlke, K., D. W. Cramer, D. Trichopoulos, and C. S. Mantzoros. 1998. Insulin-like growth factor-I in relation to premenopausal ductal carcinoma in situ of the breast. Epidemiology 9:570–3.PubMedCrossRefGoogle Scholar
  12. Bonnette, S. G., and D. L. Hadsell. 2001. Targeted disruption of the IGF-I receptor gene decreases cellular proliferation in mammary terminal end buds. Endocrinology 142:4937–45.PubMedCrossRefGoogle Scholar
  13. Bruning, P. F., J. Van Doorn, J. M. Bonfrer, P. A. Van Noord, C. M. Korse, T. C. Linders, and A. A. Hart. 1995. Insulin-like growth-factor-binding protein 3 is decreased in early-stage operable pre-menopausal breast cancer. Int J Cancer 62:266–70.PubMedCrossRefGoogle Scholar
  14. Camirand, A., Y. Lu, and M. Pollak. 2002. Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells. Med Sci Monit 8:BR521–6.Google Scholar
  15. Carboni, J. M., M. Wittman, Z. Yang, F. Lee, A. Greer, W. Hurlburt, S. Hillerman, C. Cao, G. H. Cantor, J. Dell-John, C. Chen, L. Discenza, K. Menard, A. Li, G. Trainor, D. Vyas, R. Kramer, R. M. Attar, and M. M. Gottardis. 2009. BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR. Mol Cancer Ther 8:3341–9.PubMedCrossRefGoogle Scholar
  16. Clemmons, D. R. 2007. Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer. Nat Rev Drug Discov 6:821–33.PubMedCrossRefGoogle Scholar
  17. Creighton, C. J., A. Casa, Z. Lazard, S. Huang, A. Tsimelzon, S. G. Hilsenbeck, C. K. Osborne, and A. V. Lee. 2008. Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. J Clin Oncol 26:4078–85.PubMedCrossRefGoogle Scholar
  18. Dalmizrak, O., A. Wu, J. Chen, H. Sun, F. E. Utama, D. Zambelli, T. H. Tran, H. Rui, and R. Baserga. 2007. Insulin receptor substrate-1 regulates the transformed phenotype of BT-20 human mammary cancer cells. Cancer Res 67:2124–30.PubMedCrossRefGoogle Scholar
  19. Damon, S. E., S. R. Plymate, J. M. Carroll, C. C. Sprenger, C. Dechsukhum, J. L. Ware, and C. T. Roberts, Jr. 2001. Transcriptional regulation of insulin-like growth factor-I receptor gene expression in prostate cancer cells. Endocrinology 142:21–7.PubMedCrossRefGoogle Scholar
  20. Espelund, U., S. Cold, J. Frystyk, H. Orskov, and A. Flyvbjerg. 2008. Elevated free IGF2 levels in localized, early-stage breast cancer in women. Eur J Endocrinol 159:595–601.PubMedCrossRefGoogle Scholar
  21. Fagan, D. H., and D. Yee. 2008. Crosstalk between IGF1R and estrogen receptor signaling in breast cancer. J Mammary Gland Biol Neoplasia 13:423–9.PubMedCrossRefGoogle Scholar
  22. Favoni, R. E., A. de Cupis, F. Ravera, C. Cantoni, P. Pirani, A. Ardizzoni, D. Noonan, and R. Biassoni. 1994. Expression and function of the insulin-like growth factor I system in human non-small-cell lung cancer and normal lung cell lines. Int J Cancer 56:858–66.PubMedCrossRefGoogle Scholar
  23. Fletcher, O., L. Gibson, N. Johnson, D. R. Altmann, J. M. Holly, A. Ashworth, J. Peto, and S. Silva Idos. 2005. Polymorphisms and circulating levels in the insulin-like growth factor system and risk of breast cancer: a systematic review. Cancer Epidemiol Biomarkers Prev 14:2–19.PubMedGoogle Scholar
  24. Furlanetto, R. W., and J. N. DiCarlo. 1984. Somatomedin-C receptors and growth effects in human breast cells maintained in long-term tissue culture. Cancer Res 44:2122–8.PubMedGoogle Scholar
  25. Goetsch, L., A. Gonzalez, O. Leger, A. Beck, P. J. Pauwels, J. F. Haeuw, and N. Corvaia. 2005. A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int J Cancer 113:316–28.PubMedCrossRefGoogle Scholar
  26. Gunter, M. J., D. R. Hoover, H. Yu, S. Wassertheil-Smoller, T. E. Rohan, J. E. Manson, J. Li, G. Y. Ho, X. Xue, G. L. Anderson, R. C. Kaplan, T. G. Harris, B. V. Howard, J. Wylie-Rosett, R. D. Burk, and H. D. Strickler. 2009. Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 101:48–60.PubMedGoogle Scholar
  27. Haines, I. E., and G. L. Miklos. 2008. Paclitaxel plus bevacizumab for metastatic breast cancer. N Engl J Med 358:1637; author reply 1637–8.Google Scholar
  28. Hankinson, S. E., W. C. Willett, G. A. Colditz, D. J. Hunter, D. S. Michaud, B. Deroo, B. Rosner, F. E. Speizer, and M. Pollak. 1998. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351:1393–6.PubMedCrossRefGoogle Scholar
  29. Hassan, A. B., and V. M. Macaulay. 2002. The insulin-like growth factor system as a therapeutic target in colorectal cancer. Ann Oncol 13:349–56.PubMedCrossRefGoogle Scholar
  30. Hopfner, M., A. P. Sutter, A. Huether, V. Baradari, and H. Scherubl. 2006. Tyrosine kinase of insulin-like growth factor receptor as target for novel treatment and prevention strategies of colorectal cancer. World J Gastroenterol 12:5635–43.PubMedGoogle Scholar
  31. Houghton, A. M., D. M. Rzymkiewicz, H. Ji, A. D. Gregory, E. E. Egea, H. E. Metz, D. B. Stolz, S. R. Land, L. A. Marconcini, C. R. Kliment, K. M. Jenkins, K. A. Beaulieu, M. Mouded, S. J. Frank, K. K. Wong, and S. D. Shapiro. 2010. Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth. Nat Med 16:219–23.PubMedCrossRefGoogle Scholar
  32. Jemal, A., R. Siegel, J. Xu, and E. Ward. Cancer Statistics, 2010. CA Cancer J Clin.Google Scholar
  33. Jerome, L., N. Alami, S. Belanger, V. Page, Q. Yu, J. Paterson, L. Shiry, M. Pegram, and B. Leyland-Jones. 2006. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo. Cancer Res 66:7245–52.PubMedCrossRefGoogle Scholar
  34. Jerome, L., L. Shiry, and B. Leyland-Jones. 2003. Deregulation of the IGF axis in cancer: epidemiological evidence and potential therapeutic interventions. Endocr Relat Cancer 10:561–78.PubMedCrossRefGoogle Scholar
  35. Jones, J. I., A. Gockerman, W. H. Busby, Jr., G. Wright, and D. R. Clemmons. 1993. Insulin-like growth factor binding protein 1 stimulates cell migration and binds to the alpha 5 beta 1 integrin by means of its Arg-Gly-Asp sequence. Proc Natl Acad Sci USA 90:10553–7.PubMedCrossRefGoogle Scholar
  36. Juul, A., K. Holm, K. W. Kastrup, S. A. Pedersen, K. F. Michaelsen, T. Scheike, S. Rasmussen, J. Muller, and N. E. Skakkebaek. 1997. Free insulin-like growth factor I serum levels in 1430 healthy children and adults, and its diagnostic value in patients suspected of growth hormone deficiency. J Clin Endocrinol Metab 82:2497–502.PubMedCrossRefGoogle Scholar
  37. Kalla Singh, S., Q. W. Tan, C. Brito, M. De Leon, C. Garberoglio, and D. De Leon. 2010. Differential insulin-like growth factor II (IGF-II) expression: A potential role for breast cancer survival disparity. Growth Horm IGF Res 20:162–70.PubMedCrossRefGoogle Scholar
  38. Kostler, W. J., G. Hudelist, W. Rabitsch, K. Czerwenka, R. Muller, C. F. Singer, and C. C. Zielinski. 2006. Insulin-like growth factor-1 receptor (IGF-1R) expression does not predict for resistance to trastuzumab-based treatment in patients with Her-2/neu overexpressing metastatic breast cancer. J Cancer Res Clin Oncol 132:9–18.PubMedCrossRefGoogle Scholar
  39. Law, J. H., G. Habibi, K. Hu, H. Masoudi, M. Y. Wang, A. L. Stratford, E. Park, J. M. Gee, P. Finlay, H. E. Jones, R. I. Nicholson, J. Carboni, M. Gottardis, M. Pollak, and S. E. Dunn. 2008. Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 68:10238–46.PubMedCrossRefGoogle Scholar
  40. LeRoith, D. 1997. Seminars in medicine of the Beth Israel Deaconess Medical Center. Insulin-like growth factors. N Engl J Med 336:633–40.Google Scholar
  41. Lee, A. V., S. G. Hilsenbeck, and D. Yee. 1998. IGF system components as prognostic markers in breast cancer. Breast Cancer Res Treat 47:295–302.PubMedCrossRefGoogle Scholar
  42. LeRoith, D., and C. T. Roberts, Jr. 1993. Insulin-like growth factors and their receptors in normal physiology and pathological states. J Pediatr Endocrinol 6:251–5.PubMedCrossRefGoogle Scholar
  43. Li, B. D., M. J. Khosravi, H. J. Berkel, A. Diamandi, M. A. Dayton, M. Smith, and H. Yu. 2001. Free insulin-like growth factor-I and breast cancer risk. Int J Cancer 91:736–9.PubMedCrossRefGoogle Scholar
  44. Mardilovich, K., and L. M. Shaw. 2009. Hypoxia regulates insulin receptor substrate-2 expression to promote breast carcinoma cell survival and invasion. Cancer Res 69:8894–901.PubMedCrossRefGoogle Scholar
  45. McGuire, W. L., Jr., J. G. Jackson, J. A. Figueroa, S. Shimasaki, D. R. Powell, and D. Yee. 1992. Regulation of insulin-like growth factor-binding protein (IGFBP) expression by breast cancer cells: use of IGFBP-1 as an inhibitor of insulin-like growth factor action. J Natl Cancer Inst 84:1336–41.PubMedCrossRefGoogle Scholar
  46. McKinnon, T., C. Chakraborty, L. M. Gleeson, P. Chidiac, and P. K. Lala. 2001. Stimulation of human extravillous trophoblast migration by IGF-II is mediated by IGF type 2 receptor involving inhibitory G protein(s) and phosphorylation of MAPK. J Clin Endocrinol Metab 86:3665–74.PubMedCrossRefGoogle Scholar
  47. Migliaccio, I., M. F. Wu, C. Gutierrez, L. Malorni, S. K. Mohsin, D. C. Allred, S. G. Hilsenbeck, C. K. Osborne, H. Weiss, and A. V. Lee. 2009. Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancer. Breast Cancer Res Treat.Google Scholar
  48. Miller, T. W., M. Perez-Torres, A. Narasanna, M. Guix, O. Stal, G. Perez-Tenorio, A. M. Gonzalez-Angulo, B. T. Hennessy, G. B. Mills, J. P. Kennedy, C. W. Lindsley, and C. L. Arteaga. 2009. Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer. Cancer Res 69:4192–201.PubMedCrossRefGoogle Scholar
  49. Mohan, S., and D. J. Baylink. 2002. IGF-binding proteins are multifunctional and act via IGF-dependent and -independent mechanisms. J Endocrinol 175:19–31.PubMedCrossRefGoogle Scholar
  50. Mu, L., D. Katsaros, A. Wiley, L. Lu, I. A. de la Longrais, S. Smith, S. Khubchandani, O. Sochirca, R. Arisio, and H. Yu. 2009. Peptide concentrations and mRNA expression of IGF-I, IGF-II and IGFBP-3 in breast cancer and their associations with disease characteristics. Breast Cancer Res Treat 115:151–62.PubMedCrossRefGoogle Scholar
  51. Muti, P., T. Quattrin, B. J. Grant, V. Krogh, A. Micheli, H. J. Schunemann, M. Ram, J. L. Freudenheim, S. Sieri, M. Trevisan, and F. Berrino. 2002. Fasting glucose is a risk factor for breast cancer: a prospective study. Cancer Epidemiol Biomarkers Prev 11:1361–8.PubMedGoogle Scholar
  52. Osborne, C. K., E. B. Coronado, L. J. Kitten, C. I. Arteaga, S. A. Fuqua, K. Ramasharma, M. Marshall, and C. H. Li. 1989. Insulin-like growth factor-II (IGF-II): a potential autocrine/paracrine growth factor for human breast cancer acting via the IGF-I receptor. Mol Endocrinol 3:1701–9.PubMedCrossRefGoogle Scholar
  53. Palsgaard, J., A. E. Brown, M. Jensen, R. Borup, M. Walker, and P. De Meyts. 2009. Insulin-like growth factor I (IGF-I) is a more potent regulator of gene expression than insulin in primary human myoblasts and myotubes. Growth Horm IGF Res 19:168–78.PubMedCrossRefGoogle Scholar
  54. Papa, V., B. Gliozzo, G. M. Clark, W. L. McGuire, D. Moore, Y. Fujita-Yamaguchi, R. Vigneri, I. D. Goldfine, and V. Pezzino. 1993. Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer. Cancer Res 53:3736–40.PubMedGoogle Scholar
  55. Perks, C. M., and J. M. Holly. 2008. IGF binding proteins (IGFBPs) and regulation of breast cancer biology. J Mammary Gland Biol Neoplasia 13:455–69.PubMedCrossRefGoogle Scholar
  56. Perks, C. M., P. V. Newcomb, M. R. Norman, and J. M. Holly. 1999. Effect of insulin-like growth factor binding protein-1 on integrin signalling and the induction of apoptosis in human breast cancer cells. J Mol Endocrinol 22:141–50.PubMedCrossRefGoogle Scholar
  57. Peyrat, J. P., J. Bonneterre, B. Hecquet, P. Vennin, M. M. Louchez, C. Fournier, J. Lefebvre, and A. Demaille. 1993. Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. Eur J Cancer 29A:492–7.PubMedCrossRefGoogle Scholar
  58. Pitts, T. M., A. C. Tan, G. N. Kulikowski, J. J. Tentler, A. M. Brown, S. A. Flanigan, S. Leong, C. D. Coldren, F. R. Hirsch, M. Varella-Garcia, C. Korch, and S. G. Eckhardt. 2010. Development of an integrated genomic classifier for a novel agent in colorectal cancer: approach to individualized therapy in early development. Clin Cancer Res 16:3193–204.PubMedCrossRefGoogle Scholar
  59. Pollak, M. N., J. F. Perdue, R. G. Margolese, K. Baer, and M. Richard. 1987. Presence of somatomedin receptors on primary human breast and colon carcinomas. Cancer Lett 38:223–30.PubMedCrossRefGoogle Scholar
  60. Probst-Hensch, N. M., J. H. Steiner, P. Schraml, Z. Varga, U. Zurrer-Hardi, M. Storz, D. Korol, M. K. Fehr, D. Fink, B. C. Pestalozzi, U. M. Lutolf, J. P. Theurillat, and H. Moch. 2010. IGFBP2 and IGFBP3 protein expressions in human breast cancer: association with hormonal factors and obesity. Clin Cancer Res 16:1025–32.PubMedCrossRefGoogle Scholar
  61. Renehan, A. G., M. Egger, C. Minder, S. T. O’Dwyer, S. M. Shalet, and M. Zwahlen. 2005. IGF-I, IGF binding protein-3 and breast cancer risk: comparison of 3 meta-analyses. Int J Cancer 115:1006–7; author reply 1008.Google Scholar
  62. Renehan, A. G., M. Zwahlen, C. Minder, S. T. O’Dwyer, S. M. Shalet, and M. Egger. 2004. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363:1346–53.PubMedCrossRefGoogle Scholar
  63. Rinaldi, S., P. H. Peeters, F. Berrino, L. Dossus, C. Biessy, A. Olsen, A. Tjonneland, K. Overvad, F. Clavel-Chapelon, M. C. Boutron-Ruault, B. Tehard, G. Nagel, J. Linseisen, H. Boeing, P. H. Lahmann, A. Trichopoulou, D. Trichopoulos, M. Koliva, D. Palli, S. Panico, R. Tumino, C. Sacerdote, C. H. van Gils, P. van Noord, D. E. Grobbee, H. B. Bueno-de-Mesquita, C. A. Gonzalez, A. Agudo, M. D. Chirlaque, A. Barricarte, N. Larranaga, J. R. Quiros, S. Bingham, K. T. Khaw, T. Key, N. E. Allen, A. Lukanova, N. Slimani, R. Saracci, E. Riboli, and R. Kaaks. 2006. IGF-I, IGFBP-3 and breast cancer risk in women: The European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer 13:593–605.PubMedCrossRefGoogle Scholar
  64. Sabbatini, P., J. L. Rowand, A. Groy, S. Korenchuk, Q. Liu, C. Atkins, M. Dumble, J. Yang, K. Anderson, B. J. Wilson, K. A. Emmitte, S. K. Rabindran, and R. Kumar. 2009. Antitumor activity of GSK1904529A, a small-molecule inhibitor of the insulin-like growth factor-I receptor tyrosine kinase. Clin Cancer Res 15:3058–67.PubMedCrossRefGoogle Scholar
  65. Sachdev, D., and D. Yee. 2007. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther 6:1–12.PubMedCrossRefGoogle Scholar
  66. Shetty, P. J., S. Movva, N. Pasupuleti, B. Vedicherlla, K. K. Vattam, S. Venkatasubramanian, Y. R. Ahuja, and Q. Hasan. 2010. Regulation of IGF2 transcript and protein expression by altered methylation in breast cancer. J Cancer Res Clin Oncol.Google Scholar
  67. Shi, R., H. Yu, J. McLarty, and J. Glass. 2004. IGF-I and breast cancer: a meta-analysis. Int J Cancer 111:418–23.PubMedCrossRefGoogle Scholar
  68. So, A. I., R. J. Levitt, B. Eigl, L. Fazli, M. Muramaki, S. Leung, M. C. Cheang, T. O. Nielsen, M. Gleave, and M. Pollak. 2008. Insulin-like growth factor binding protein-2 is a novel therapeutic target associated with breast cancer. Clin Cancer Res 14:6944–54.PubMedCrossRefGoogle Scholar
  69. Spentzos, D., S. A. Cannistra, F. Grall, D. A. Levine, K. Pillay, T. A. Libermann, and C. S. Mantzoros. 2007. IGF axis gene expression patterns are prognostic of survival in epithelial ovarian cancer. Endocr Relat Cancer 14:781–90.PubMedCrossRefGoogle Scholar
  70. Stoeltzing, O., W. Liu, N. Reinmuth, F. Fan, A. A. Parikh, C. D. Bucana, D. B. Evans, G. L. Semenza, and L. M. Ellis. 2003. Regulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by an insulin-like growth factor-I receptor autocrine loop in human pancreatic cancer. Am J Pathol 163:1001–11.PubMedCrossRefGoogle Scholar
  71. Sueoka, N., H. Y. Lee, S. Wiehle, R. J. Cristiano, B. Fang, L. Ji, J. A. Roth, W. K. Hong, P. Cohen, and J. M. Kurie. 2000. Insulin-like growth factor binding protein-6 activates programmed cell death in non-small cell lung cancer cells. Oncogene 19:4432–6.PubMedCrossRefGoogle Scholar
  72. Sugumar, A., Y. C. Liu, Q. Xia, Y. S. Koh, and K. Matsuo. 2004. Insulin-like growth factor (IGF)-I and IGF-binding protein 3 and the risk of premenopausal breast cancer: a meta-analysis of literature. Int J Cancer 111:293–7.PubMedCrossRefGoogle Scholar
  73. Tamemoto, H., T. Kadowaki, K. Tobe, T. Yagi, H. Sakura, T. Hayakawa, Y. Terauchi, K. Ueki, Y. Kaburagi, S. Satoh, and et al. 1994. Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. Nature 372:182–6.PubMedCrossRefGoogle Scholar
  74. Taverne, C. W., M. Verheus, J. D. McKay, R. Kaaks, F. Canzian, D. E. Grobbee, P. H. Peeters, and C. H. van Gils. 2010. Common genetic variation of insulin-like growth factor-binding protein 1 (IGFBP-1), IGFBP-3, and acid labile subunit in relation to serum IGF-I levels and mammographic density. Breast Cancer Res Treat.Google Scholar
  75. Toniolo, P., P. F. Bruning, A. Akhmedkhanov, J. M. Bonfrer, K. L. Koenig, A. Lukanova, R. E. Shore, and A. Zeleniuch-Jacquotte. 2000. Serum insulin-like growth factor-I and breast cancer. Int J Cancer 88:828–32.PubMedCrossRefGoogle Scholar
  76. Turner, B. C., B. G. Haffty, L. Narayanan, J. Yuan, P. A. Havre, A. A. Gumbs, L. Kaplan, J. L. Burgaud, D. Carter, R. Baserga, and P. M. Glazer. 1997. Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res 57:3079–83.PubMedGoogle Scholar
  77. Vadgama, J. V., Y. Wu, G. Datta, H. Khan, and R. Chillar. 1999. Plasma insulin-like growth factor-I and serum IGF-binding protein 3 can be associated with the progression of breast cancer, and predict the risk of recurrence and the probability of survival in African-American and Hispanic women. Oncology 57:330–40.PubMedCrossRefGoogle Scholar
  78. Van den Berg, C. L., G. N. Cox, C. A. Stroh, S. G. Hilsenbeck, C. N. Weng, M. J. McDermott, D. Pratt, C. K. Osborne, E. B. Coronado-Heinsohn, and D. Yee. 1997. Polyethylene glycol conjugated insulin-like growth factor binding protein-1 (IGFBP-1) inhibits growth of breast cancer in athymic mice. Eur J Cancer 33:1108–13.PubMedCrossRefGoogle Scholar
  79. Volpert, O., D. Jackson, N. Bouck, and D. I. Linzer. 1996. The insulin-like growth factor II/mannose 6-phosphate receptor is required for proliferin-induced angiogenesis. Endocrinology 137:3871–6.PubMedCrossRefGoogle Scholar
  80. White, M. F. 1998. The IRS-signaling system: a network of docking proteins that mediate insulin and cytokine action. Recent Prog Horm Res 53:119–38.PubMedGoogle Scholar
  81. Winston, R., P. C. Kao, and D. T. Kiang. 1994. Regulation of insulin-like growth factors by antiestrogen. Breast Cancer Res Treat 31:107–15.PubMedCrossRefGoogle Scholar
  82. Withers, D. J., J. S. Gutierrez, H. Towery, D. J. Burks, J. M. Ren, S. Previs, Y. Zhang, D. Bernal, S. Pons, G. I. Shulman, S. Bonner-Weir, and M. F. White. 1998. Disruption of IRS-2 causes type 2 diabetes in mice. Nature 391:900–4.PubMedCrossRefGoogle Scholar
  83. Yee, D., and A. V. Lee. 2000. Crosstalk between the insulin-like growth factors and estrogens in breast cancer. J Mammary Gland Biol Neoplasia 5:107–15.PubMedCrossRefGoogle Scholar
  84. Yu, H., F. Jin, X. O. Shu, B. D. Li, Q. Dai, J. R. Cheng, H. J. Berkel, and W. Zheng. 2002. Insulin-like growth factors and breast cancer risk in Chinese women. Cancer Epidemiol Biomarkers Prev 11:705–12.PubMedGoogle Scholar
  85. Zhang, X., and D. Yee. 2002. Insulin-like growth factor binding protein-1 (IGFBP-1) inhibits breast cancer cell motility. Cancer Res 62:4369–75.PubMedGoogle Scholar
  86. Zofkova, I. 2003. Pathophysiological and clinical importance of insulin-like growth factor-I with respect to bone metabolism. Physiol Res 52:657–79.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Department of PharmacologyUniversity of MinnesotaMinneapolisUSA
  2. 2.Masonic Cancer CenterUniversity of MinnesotaMinneapolisUSA
  3. 3.Department of MedicineUniversity of MinnesotaMinneapolisUSA

Personalised recommendations